Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

Since metastatic colorectal cancer (CRC) is a leading cause of cancer-related death, therapeutic approaches overcoming primary and acquired therapy resistance are an urgent medical need. In this study, the efficacy and toxicity of high-affinity inhibitors targeting antiapoptotic BCL-2 proteins (BCL-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Death Dis
Auteurs principaux: Scherr, Anna-Lena, Mock, Andreas, Gdynia, Georg, Schmitt, Nathalie, Heilig, Christoph E., Korell, Felix, Rhadakrishnan, Praveen, Hoffmeister, Paula, Metzeler, Klaus H., Schulze-Osthoff, Klaus, Illert, Anna L., Boerries, Melanie, Trojan, Jörg, Waidmann, Oliver, Falkenhorst, Johanna, Siveke, Jens, Jost, Philipp J., Bitzer, Michael, Malek, Nisar P., Vecchione, Loredana, Jelas, Ivan, Brors, Benedikt, Glimm, Hanno, Stenzinger, Albrecht, Grekova, Svetlana P., Gehrig, Tobias, Schulze-Bergkamen, Henning, Jäger, Dirk, Schirmacher, Peter, Heikenwalder, Mathias, Goeppert, Benjamin, Schneider, Martin, Fröhling, Stefan, Köhler, Bruno C.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568722/
https://ncbi.nlm.nih.gov/pubmed/33070156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-03092-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires